MaxCyte, Inc.

MaxCyte, Inc.

MXCT·NASDAQ

$1.23

-0.22%
HealthcareMedical - Devices

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$131.76M
EPS-0.4200
P/E Ratio-3.70
Earnings Date08/12/2026

mxct

Total Other Income Expenses Net

Last Annual Value

-1.08M

3-Year CAGR

-9%

5-Year CAGR

-7%

10-Year CAGR

-5%

MaxCyte, Inc.

MaxCyte, Inc. Competitors Analysis of Total Other Income Expenses Net

MXCT · NASDAQ
CompanyTotal Other Income Expenses Net
CAGR 3Y
CAGR 5Y
CAGR 10Y
MXCT logo
MaxCyte, Inc.
NASDAQ:MXCT
-1.08M
N/AN/AN/A 
-113.05M
N/AN/AN/A
-9.16M
N/AN/AN/A
2.32M
31.9%N/AN/A
HYPR logo
Hyperfine, Inc.
NASDAQ:HYPR
1.51M
-27.0%145.3%N/A
309.00K
-57.9%N/AN/A
-1.32M
N/AN/AN/A
-12.27M
N/AN/AN/A
OWLT logo
Owlet, Inc.
NYSE:OWLT
-31.40M
N/AN/AN/A
-142.58M
N/AN/AN/A
LNSR logo
LENSAR, Inc.
NASDAQ:LNSR
-9.70M
N/AN/AN/A
MaxCyte, Inc.

MaxCyte, Inc. Fair Value Envelope

MXCT · NASDAQ

Our analysis suggests that MXCT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.23, this represents a potential HIDDEN relative to our calculated worth for MaxCyte, Inc..

Intrinsic Value
Current Price: $1.23